Compile Data Set for Download or QSAR
maximum 50k data
Found 576 with Last Name = 'allan' and Initial = 'ce'
TargetVasopressin V2 receptor(Homo sapiens (Human))
Vantia

Curated by ChEMBL
LigandPNGBDBM50246925(1-(4-[3-(2,6-Difluorophenyl)ureidomethyl]-3-methyl...)
Affinity DataKi:  200nMAssay Description:Binding affinity to human vasopressin V2 receptor expressed in HEK293 cells by radioligand binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Vantia

Curated by ChEMBL
LigandPNGBDBM50246575(1-(2-Methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-y...)
Affinity DataKi:  2.00E+3nMAssay Description:Binding affinity to human vasopressin V2 receptor expressed in HEK293 cells by radioligand binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOxytocin receptor(Homo sapiens (Human))
Vantia

Curated by ChEMBL
LigandPNGBDBM50246925(1-(4-[3-(2,6-Difluorophenyl)ureidomethyl]-3-methyl...)
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to oxytocin receptor (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOxytocin receptor(Homo sapiens (Human))
Vantia

Curated by ChEMBL
LigandPNGBDBM50246575(1-(2-Methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-y...)
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to oxytocin receptor (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOxytocin receptor(Homo sapiens (Human))
Vantia

Curated by ChEMBL
LigandPNGBDBM50246890(1-(4-[3-(2,6-Difluorophenyl)ureidomethyl]benzoyl)-...)
Affinity DataKi: >1.00E+4nMAssay Description:Binding affinity to oxytocin receptor (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187100(US9670157, 114 3-Methyl-1-[4-(4-methyl-pyrazol-1-y...)
Affinity DataIC50:  0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187100(US9670157, 114 3-Methyl-1-[4-(4-methyl-pyrazol-1-y...)
Affinity DataIC50:  0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187097(US9670157, 111 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187104(US9670157, 118 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187097(US9670157, 111 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187104(US9670157, 118 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187110(US9670157, 124 3-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187092(US9670157, 106 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187110(US9670157, 124 3-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187099(US9670157, 113 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187099(US9670157, 113 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187092(US9670157, 106 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187098(US9670157, 112 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187098(US9670157, 112 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187093(US9670157, 107 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187112(US9670157, 126 1-(2-Methyl-quinolin-6-ylmethyl)-3-...)
Affinity DataIC50:  3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187111(US9670157, 125 5-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50:  3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187093(US9670157, 107 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187112(US9670157, 126 1-(2-Methyl-quinolin-6-ylmethyl)-3-...)
Affinity DataIC50:  3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187111(US9670157, 125 5-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50:  3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187087(US9670157, 101 2,5-Dimethyl-1-[4-(4-methyl-pyrazol...)
Affinity DataIC50:  4nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187087(US9670157, 101 2,5-Dimethyl-1-[4-(4-methyl-pyrazol...)
Affinity DataIC50:  4nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187095(US9670157, 109 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187095(US9670157, 109 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186837(US9670157, 3 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50:  6nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186837(US9670157, 3 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50:  6nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186920(US9670157, 86 1-[4-(3,5-Dimethyl-pyrazol-1-ylmethy...)
Affinity DataIC50:  7nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186920(US9670157, 86 1-[4-(3,5-Dimethyl-pyrazol-1-ylmethy...)
Affinity DataIC50:  7nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187097(US9670157, 111 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  8nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM362300(5-Methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl...)
Affinity DataIC50:  8nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187105(US9670157, 119 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  9nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187105(US9670157, 119 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50:  9nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187088(US9670157, 102 1-Ethyl-4-methyl-5-[4-(4-methyl-pyr...)
Affinity DataIC50:  11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186952(US9670157, 94 2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-...)
Affinity DataIC50:  11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186919(US9670157, 85 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-b...)
Affinity DataIC50:  11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187088(US9670157, 102 1-Ethyl-4-methyl-5-[4-(4-methyl-pyr...)
Affinity DataIC50:  11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186952(US9670157, 94 2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-...)
Affinity DataIC50:  11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186919(US9670157, 85 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-b...)
Affinity DataIC50:  11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186836(US9670157, 2 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50:  15nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186836(US9670157, 2 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50:  15nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186954(US9670157, 95 1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyri...)
Affinity DataIC50:  16nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM362280(1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl...)
Affinity DataIC50:  16nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187115(US9670157, 129 1-(2-Pyrrolidin-1-yl-pyridin-4-ylme...)
Affinity DataIC50:  24nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187115(US9670157, 129 1-(2-Pyrrolidin-1-yl-pyridin-4-ylme...)
Affinity DataIC50:  24nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186956(US9670157, 97 2,5-Dimethyl-1-[4-(4-methyl-pyrazol-...)
Affinity DataIC50:  28nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 576 total ) | Next | Last >>
Jump to: